Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) Overview
  3. Therapeutics Development
  4. Pipeline Products for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Overview
  5. Pipeline Products for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Comparative Analysis
  6. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Therapeutics under Development by Companies
  7. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Therapeutics under Investigation by Universities/Institutes
  8. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Companies
  13. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Investigation by Universities/Institutes
  14. Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Companies Involved in Therapeutics Development
  • Agenus, Inc.
  • Aurigene Discovery Technologies Limited
  • BeiGene, Ltd.
  • Cellular Biomedicine Group, Inc.
  • CytomX Therapeutics, Inc.
  • Enumeral Biomedical Holdings, Inc.
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Immunovo BV
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Jounce Therapeutics, Inc.
  • MacroGenics, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merus B.V.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Symphogen A/S
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tesaro, Inc.
  • Theravectys SA
  • Tikcro Technologies, Ltd.
  • Vyriad

For more information visit http://www.researchandmarkets.com/research/ccwqml/programmed_cell

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Musculoskeletal Disorders Drugs